



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re: Application of DEBINSKI et al.

Serial No.: 10/075,823

Examiner:

Date Filed: February 12, 2002


Group:

For: VEGF-D EXPRESSION IN BRAIN CANCER

RECEIVED  
JAN 08 2003  
TECH CENTER 1600/2000

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on January 2, 2003.

  
Stanley A. Kim, Ph.D., Esq.

Reg. No. 42,730

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to the Duty to Disclose under 37 CFR 1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed.

The claimed invention is believed patentable over the disclosures enclosed. This citation is intended to give the Examiner an opportunity to make an independent evaluation. No representations are made regarding these materials.

Respectfully submitted,

AKERMAN SENTERFITT

Dated: January 2, 2003

  
Stanley A. Kim, Ph.D., Esq.  
Registration No. 42,730  
222 Lakeview Avenue, Suite 400  
West Palm Beach, FL 33402-3188  
Tel: 561-653-5000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of DEBINSKI et al.

Serial No.: 10/075,823

Examiner:

Date Filed: February 12, 2002


Group:

For: VEGF-D EXPRESSION IN BRAIN CANCER

RECEIVED  
JAN 08 2003  
TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on January 2, 2003.

  
Stanley A. Kim, Ph.D., Esq.

Reg. No. 42,730

Commissioner for Patents  
Washington, DC 20231

TRANSMITTAL LETTER

Dear Sir:

Please find enclosed for filing the following:

Supplemental Information Disclosure Statement, with PTO-1449, and references;  
and  
 1 postcard.

Although no fee is believed due, please charge any underpayment to Deposit Account No. 50-0951. This letter is submitted in duplicate.


Respectfully submitted,

AKERMAN SENTERFITT

Dated: January 2, 2003

  
Stanley A. Kim, Ph.D., Esq.  
Registration No. 42,730  
222 Lakeview Avenue, Suite 400  
West Palm Beach, FL 33402-3188  
Tel: 561-653-5000

Docket No. 6460-41



RECEIVED  
JAN 9 2003  
TECH CENTER 1600/2900

Sheet 1 of 4

Form PTO-1449  
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
6460-41

APPLICATION NO.  
10/075,823

APPLICANT  
Debinski et al.

FILING DATE  
February 12, 2002

GROUP

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Goldman et al., "Epidermal Growth Factor Stimulates Vascular Endothelial Growth Factor Production by Human Malignant Glioma Cells: A Model of Glioblastoma Multiforme Pathophysiology," Molecular Biology of the Cell, 4: 121-133, 1993
		Kerbel et al., "Establishing a Link between Oncogenes and Tumor Angiogenesis," Molecular Medicine, 4: 286-295, 1998
		Orlandini et al., "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family," Proc. Natl. Acad. Sci. USA, 93: 11675-11680, 1996
		Achen et al., "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," Proc. Natl. Acad. Sci. USA, 95: 548-553, 1998
		Marconcini et al., "c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis <i>in vivo</i> and <i>in vitro</i> ," Proc. Natl. Acad. Sci. USA, 96: 9671-9676, 1999
		Mintz A. and W. Debinski, "Cancer Genetics/Epigenetics and the X Chromosome: Possible New Links for Malignant Glioma Pathogenesis and Immune-Based Therapies," Critical Reviews in Oncogenesis, 11: 77-95, 2000

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

5 2003

JAN 06 2003

Sheet 2 of 4

Form PTO-1449  
(Rev. 2-88)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
6460-41APPLICATION NO.  
10/075,823APPLICANT  
Debinski et al.FILING DATE  
February 12, 2002

GROUP

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Achen et al., "Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3," Eur. J. Biochem. 267: 2505-2515, 2000
		Stacker et al., "Biosynthesis of Vascular Endothelial Growth Factor-D Involves Proteolytic Processing Which Generates Non-covalent Homodimers," The Journal of Biological Chemistry, 274: 32127-32136, 1999
		Halfter et al., "Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor," Journal of Neuro Oncology, 39: 1-18, 1998
		Bergers et al., "Transcriptional Activation of the <i>fra-1</i> Gene by AP-1 Is Mediated by Regulatory Sequences in the First Intron," Molecular and Cellular Biology, 15: 3748-3758, 1995
		Tulchinsky, E., "Fos family members: regulation, structure and role in oncogenic transformation," Histol Histopathol, 15: 921-928, 2000
		Lilja et al., "ABNORMAL EXPRESSION OF OSM, CNTF AND LIF IN HUMAN BRAIN TUMORS," Neuro-Oncology, 2: S22

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 4 of 4

1449  
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
6460-41

APPLICATION NO.  
10/075,823

APPLICANT  
Debinski et al.

FILING DATE  
February 12, 2002

GROUP

RECEIVED  
JAN 08 2003  
TECH CENTER 1600/2800

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Strawn et al., "Flk-1 as a Target for Tumor Growth Inhibition," Cancer Research, 56: 3540-3545, 1996
			Prewett et al., "Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1 Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors," Cancer Research, 59: 5209-5218, 1999
			Rubenstein et al., "Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption," Neoplasia, 2: 306-314, 2000
			Okada et al., "Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells," Proc. Natl. Acad. Sci. USA, 95: 3609-3614, 1998
			Stacker et al., "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics," Nature Medicine, 7: 186-191, 2001

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 4

DEPT. OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE PTO-1449 (Rev. 2-88)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6460-41	APPLICATION NO. 10/075,833		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Debinski et al.			
(Use several sheets if necessary)				FILING DATE February 12, 2002	GROUP		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED  
JAN 08 2003  
TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
							NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Zagzag et al., "Immunohistochemical Localization of Basic Fibroblast Growth Factor in Astrocytomas," Cancer Research, 50: 7393-7398, 1990
		Botelho et al., "Oncostatin M Stimulates c-Fos to Bind a Transcriptionally Responsive AP-1 Element within the Tissue Inhibitor of Metalloproteinase-1 Promoter," The Journal of Biological Chemistry, 273: 5211-5218, 1998
		Mohan et al., "Curcuminoids Inhibit the Angiogenic Response Stimulated by Fibroblast Growth Factor-2, Including Expression of Matrix Metalloproteinase Gelatinase B," The Journal of Biological Chemistry, 275: 10405-10412, 2000
		Nakano et al., "Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas," J. Neurosurg, 83: 298-307, 1995
		Millauer et al., "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," Nature, 367: 576-579, 1994
		Takano et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients," Cancer Research, 56: 2185-2190, 1996

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	